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Abstract
RAD51 recombinase polymerizes at the site of double-strand breaks (DSBs) where it performs DSB repair. The loss of RAD51
causes extensive chromosomal breaks, leading to apoptosis. The polymerization of RAD51 is regulated by a number of
RAD51 mediators, such as BRCA1, BRCA2, RAD52, SFR1, SWS1, and the five RAD51 paralogs, including XRCC3. We here show
that brca2-null mutant cells were able to proliferate, indicating that RAD51 can perform DSB repair in the absence of BRCA2.
We disrupted the BRCA1, RAD52, SFR1, SWS1, and XRCC3 genes in the brca2-null cells. All the resulting double-mutant cells
displayed a phenotype that was very similar to that of the brca2-null cells. We suggest that BRCA2 might thus serve as a
platform to recruit various RAD51 mediators at the appropriate position at the DNA–damage site.
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Introduction
Homologous recombination (HR) maintains genome integrity
by accurately repairing double-strand breaks (DSBs) that arise
during the mitotic cell cycle or are induced by radiotherapy [1,2].
HR also plays an important role in releasing the replication forks
that stall at damaged template DNA strands [3,4]. Thus, effective
HR makes tumor cells tolerant to the chemotherapeutic agents
that damage DNA and stall replicative DNA polymerases. Such
chemotherapeutic agents include cis-diaminedichloroplatinum(II)
(cisplatin), camptothecin, and poly(ADP-ribose) polymerase
(PARP) inhibitors, including olaparib (AstraZeneca). Cisplatin is
a crosslinking agent that generates intra- and inter-strand cross-
links and thereby stalls replicative DNA polymerases. Campto-
thecin inhibits the ligation of single-strand breaks (SSBs) that are
formed during the normal functioning of topoisomerase 1.
Resulting unrepaired SSBs are converted to DSBs upon
replication. Similarly, PARP inhibitors interfere with SSB repair
[5]. Since HR plays a major role in repairing DNA lesions
generated by camptothecin, cisplatin, and PARP inhibitors [6],
measuring HR efficiency in individual malignant tumors may help
predict the efficacy of these chemotherapeutic treatment for each
tumor [7–9].
HR-dependent DSB repair is accomplished by the following
step-wise reactions [10]. DSBs are processed by the Mre11/
Rad50/Nbs1 complex and the CtIP, Exo1 and DNA2 nucleases to
develop 39 single-strand DNA (ssDNA) tails [11–17]. RAD51, an
essential recombinase, polymerizes on these ssDNAs, leading to
the formation of nucleoprotein filaments. These filaments undergo
homology search and subsequent invasion into homologous
duplex DNA to form a D-loop structure, where they serve as a
primer for DNA synthesis [18,19]. After the extended end is
displaced from the D-loop, it anneals to its partner-end to
complete DSB repair. We know that RAD51 plays a key role in
HR in vertebrate cells, as inactivation of RAD51 results in the
accumulation of chromosomal breaks in mitotic cells and inhibits
the completion of even a single cell cycle [1,2]. The polymeriza-
tion of RAD51 at damage sites is strictly regulated by a number of
accessory factors (hereafter called RAD51 mediators), including
the five RAD51 paralogs, SWS1, RAD52, SFR1, BRCA1,
BRCA2, and PALB2 [3,20–27]. The functional relationships of
these RAD51 mediators are poorly understood, because cells
deficient in multiple RAD51 mediators have not been established.
BRCA2 was originally identified as a tumor suppressor, as
germline mutation of the BRCA2 gene results in a high risk of
developing breast, ovarian, pancreatic, prostatic, and male breast
cancer [3,20,28,29]. BRCA2 is recruited to processed DSBs, and
facilitates the assembly of RAD51 at the single-strand tail. The
middle of the BRCA2 protein has eight BRC repeats, comprising
26 amino acids. Biochemical studies have revealed that individual
BRC repeats prompt the loading of RAD51 on ssDNA [30,31].
Since no brca2-null cells have been established, the function of
BRCA2 has been postulated from the phenotypic analysis of mice
carrying an allele, extending from the N-terminus to the BRC3
motif (hereafter brca2tr) that encodes a truncated form of BRCA2.
Cells derived from brca2tr mice and brca2tr DT40 cells are able to
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camptothecin, and cisplatin [32,33]. It remains unclear whether
brca2 null cells display the same phenotype as do rad51 cells, or a
milder phenotype.
The roles of the RAD51 mediators have been characterized
by phenotypic analysis of their mutants. Mammalian brca1-
deficient cells show normal focus formation of the RPA ssDNA
binding protein but diminished RAD51 focus formation at
DSBs, indicating that BRCA1 facilitates the polymerization of
RAD51 after the resection of DSBs [15,34]. DT40 cells
deficient in any one of the five RAD51 paralogs show a very
similar phenotype, including compromised RAD51 focus
formation and the same degree of DNA damage sensitivity
[35,36], suggesting that these five proteins form a functional
unit in the promotion of RAD51 polymerization in which each
RAD51 paralog is essential for its function. No biochemical
studies have yet defined the molecular mechanisms underlying
the promotion of RAD51 assembly by BRCA1, the RAD51
paralogs, or SWS1. SWS1 is another RAD51 mediator [26],
and sws1-deficient vertebrate cells have not yet been reported.
SFR1 was originally identified in fission yeast [25], and its role
in in vitro HR reactions [37,38] as well as the phenotypic
analysis of sfr1-deficient mice have been recently reported [39].
The biochemical character of full-length human BRCA2 has
been recently documented, whereas no biochemical studies
have defined its functional interaction with other RAD51
mediators or the molecular mechanisms underlying the
promotion of RAD51 assembly by BRCA1, the RAD51
paralogs, or SWS1 [40–42].
In this paper, we addressed the function of Rad51 mediators
and their relationship in DNA-damage responses. We generated
the single Rad51 mediator mutant cells, including brca2 null, sfr1
and sws1 deficient cells from DT40 chicken cell line [43]. We also
disrupted the BRCA1, one of the RAD51 paralogs (XRCC3),
RAD52, RAD54, SWS1, and SFR1 in brca2 null deficient DT40
cells. The phenotypes of these cells were analyzed to reveal
hierarchical relationship of RAD51, BRCA2, and the other
RAD51 mediators, where RAD51 is able to operate HR without
BRCA2 while BRCA2 is required for the functioning of the other
RAD51 mediators. Hence, BRCA2 might serve as a platform to
recruit various RAD51 mediators at the appropriate position of
DNA-damage sites. Our study sheds light on the functional
relationship of RAD51 and every known RAD51 mediators for the
first time, and thereby significantly contributes to the development
of effective anti-cancer therapies.
Results
Loss of SFR1 or SWS1 has a limited impact on DNA–
damage responses
To analyze SFR1 and SWS1, we disrupted the SFR1 and SWS1
genes in DT40 cells (Figure 1A–1D). Table 1 summarizes the
selection marker genes we used to disrupt genes in this study. The
resulting sfr1 and sws1 mutant clones proliferated with nearly
normal kinetics (Figure 2) and exhibited an increase in cellular
sensitivity to cisplatin. The sfr1 mutant was sensitive also to
camptothecin and olaparib (Figure 3). Both mutants showed a
slight but significant decrease in ionizing-radiation-induced
RAD51 focus formation (Figure 4). We conclude that SFR1 and
SWS1 indeed work as RAD51 mediators, though their contribu-
tion to HR-dependent repair is less significant than that of
BRCA1, BRCA2, and the RAD51 paralogs.
The brca2-null mutant is capable of proliferating
To create brca2-null cells, we generated compound heterozygous
mutant cells (hereafter called BRCA2
2/con1 cells) (Figure 1E). The
whole coding sequence was deleted in the minus (2) allele of the -/
conditional-null allele-1 (-/con1) genotype of the BRCA2
2/con1 cells
(Coding sequence deletion allele in Figure 1F). We conditionally deleted
the con1 allele of the BRCA2
2/con1 cells by adding tamoxifen, which
activated the chimeric Cre recombinase [28] and thereby
eliminated the promoter and coding sequences, including exons
1 and 2 of the con1 BRCA2 allelic gene (BRCA2 conditional-null
allele-1 in Figure 1F). At day two of continuous tamoxifen
treatment, the vast majority of cells lost the intact BRCA2 gene in
the conditional allele, and a substantial fraction of cells began to
die. To our surprise, we were able to reproducibly establish
clonally expanding cells wherein the conditional BRCA2 allele was
deleted (BRCA2
2/2 cells, hereafter called brca2-null cells) from 10
to 20% of the tamoxifen-treated populations. We verified deletion
of the BRCA2 allele in the established clones by Southern-blot
(Figure 1G) and western-blot (Figure 1H) analysis. The ability of
the brca2-deleted cells to proliferate is in marked contrast to the
immediate cell death observed in rad51-deleted cells [1]. The
plating efficiency of the brca2-null clones was around 20%, which is
significantly lower than that of the wild-type (100%) and brca2tr
(60%) cells [33].
One obvious concern with this experiment was that expression
of the N-terminal-truncated BRCA2 protein in the Cre-mediated
deletion lines could allow for residual function. We therefore
created a second version of the conditionally inactivated BRCA2
allele, wherein sequences spanning from the promoter to intron 12
could be eliminated by induction of Cre (BRCA2 conditional-null
allele-2 in Figure S1). We exposed the resulting compound
heterozygous mutant cells to tamoxifen and confirmed reproduc-
ible establishment of BRCA2-deleted clones (Text S1). This second
brca2 conditional-null allele supported proliferation with generation
times very similar to those of the first version of the brca2-null cells
(data not shown). The more extensively deleted brca2 clones
showed a phenotype indistinguishable from that of the smaller
deletion clones, indicating that both deletions confer the null
phenotype.
BRCA2 contributes to genome maintenance to a lesser
extent than does RAD51
We assessed the proliferative properties of brca2-null clones by
monitoring their growth curve (Figure 2A and 2B) and cell cycle
(Figure 2C). Wild-type cells doubled every 8 hours and increased in
cell number by 64 times over 48 hours. The brca2-null cells
increased by 17 times over 48 hours (Figure 2A), calculated as a
Author Summary
Mutations in BRCA1 and BRCA2 predispose hereditary
breast and ovarian cancer. Such mutations sensitize to
chemotherapeutic agents, including camptothecin, cisplat-
in, and poly(ADP-ribose) polymerase (PARP) inhibitor, since
RAD51 mediators including both BRCA proteins promote
repair of DNA lesions induced by these drugs. Little is
known of functional relationship among RAD51, BRCA2,
and other RAD51 mediators, because no brca2-null cells
were available. Furthermore, the phenotype of sws1
mutants has not been documented. We here disrupted
every known RAD51 mediators and analyzed the pheno-
type of the resulting mutants in both BRCA2-deficient and
-proficient backgrounds. The understanding of the func-
tion of individual RAD51 mediators and their functional
interactions will contribute to the accurate prediction of
anti-cancer therapy efficacy.
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PLoS Genetics | www.plosgenetics.org 2 July 2011 | Volume 7 | Issue 7 | e1002148Figure 1. Gene disruption of the SFR1, SWS1, and BRCA2 loci. (A) Schematic representation of the endogenous SFR1 locus and gene-disruption
constructs carrying the puro or bsr selection marker gene. The solid boxes represent exons, and numbers right above boxes represent exon numbers.
Relevant BamHI and EcoRI sites are indicated. (B) Southern-blot analysis of genomic DNA digested by both BamHI and EcoRI was performed using the
probe DNA shown in (A). Positions of hybridizing fragments of wild-type (WT) and targeted loci are indicated. (C) Schematic representation of the
endogenous SWS1 locus and gene-disruption constructs carrying the puro or his selection marker gene. Relevant EcoRV and NotI sites are indicated.
(D) Southern-blot analysis of genomic DNA digested by EcoRV and NotI was performed with the probe DNA shown in (C). (E) Experimental methods
to generate BRCA2
2/2 and RAD51mediator
2/2/BRCA2
2/2 cells. We generated BRCA2
2/2 cells from conditional mutant BRCA2
2/con1 cells. In the minus
allele of the BRCA2
2/con1 cells, the whole coding sequence is deleted (hereafter called the coding sequence deletion allele). The structures of the
conditional-null allele-1 (con1) is shown in (F). Treatment of BRCA2
2/con1 cells with 4-OH tamoxifen (TAM) led to the generation of BRCA2
2/2 cells. To
generate RAD51mediator
2/2/BRCA2
2/2 cells, we disrupted one of the RAD51mediator genes in BRCA2
2/con1 cells. Exposure of the resulting
RAD51mediator
2/2/BRCA2
2/con1 cells to TAM led to the generation of RAD51mediator
2/2/BRCA2
2/2 cells. (F) Schematic representation of BRCA2
conditional-null allele and the brca2-null allele wherein the whole coding sequences are deleted. The conditional-null allele-1 (con1) shown on top was
described previously [33]; the structure of the coding sequence deletion allele is shown in the second row. Treatment of the BRCA2
2/con1 cells with TAM
causes deletion of the promoter and initiation codon. The relevant EcoRI sites in the conditional-null allele-1, the relevant XbaI sites in the coding
sequence deletion allele, and the position of the probes used in the Southern-blot analysis (G) are indicated. The solid boxes and arrowheads represent
the exons and loxP signals, respectively. (G) Southern-blot analysis of the conditional allele (left) and the other coding sequence deletion (2) allele
(right) in BRCA2
2/con1 cells with (+) or without (2) TAM treatment. Southern-blot analysis of EcoRI or XbaI-digested genomic DNA was performed with
the probe DNA shown in (F). (H) Western-blot analysis to verify the loss of BRCA2 protein in BRCA2
2/2 cells derived from BRCA2
2/con1 cells.
doi:10.1371/journal.pgen.1002148.g001
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PLoS Genetics | www.plosgenetics.org 3 July 2011 | Volume 7 | Issue 7 | e1002148Figure 2. Decreased cellular proliferation in brca2-null cells. (A) Growth curve for cells of the indicated genotype. (B) The relative rate of cell
growth per 8 hours (a single cell cycle for wild-type cells) plotted for cells carrying the indicated genotypes. Each value represents the averaged
results from three separate experiments. Error bars represent standard deviation. (C) Cell-cycle distribution of brca2-null cells that were pulse-labeled
with BrdU for 10 minutes and subsequently stained with FITC-conjugated anti-BrdU antibody (Y-axis, log scale) and propidium iodide (PI) (X-axis,
linear scale). The upper gate indicates cells incorporating BrdU (S phase), the lower middle gate indicates G1 cells, and the lower-right gate indicates
G2/M cells. The sub G1 fraction (lower-left gate) indicates dead cells. The number in each gate indicates the percentage of gated events.
doi:10.1371/journal.pgen.1002148.g002
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6=17) (Figure 2B). The number
of brca1, brca2tr, and xrcc3 clones [36] increased 1.6, 1.9, and 1.8
fold, respectively, over eight hours. The reduced growth kinetics of
the brca2-null cells is partly due to apoptosis in a substantial fraction
of the cell population, as evidenced by the accumulation of cells in
a sub-G1 fraction (Figure 2C).
To understand the cause of this cell death, we measured the
number of chromosome breaks in mitotic cells. Forty-six
chromosomal aberrations were detectable in 100 mitotic brca2-
null cells, larger than the number of aberrations observed in any
other RAD51-mediator mutants (Table 2). We therefore conclude
that spontaneously arising DSBs resulted in cell death in a fraction
of brca2-null cells, thus accounting for the reduced growth kinetics
(Figure 2A and 2B). The viability of the brca2-null cells reveals that
BRCA2 plays a less important role than does RAD51 in the
maintenance of genome integrity [1]. The high number of
spontaneously arising chromosomal breaks in the brca2-null cells
(Table 2) shows that BRCA2 plays a more fundamental role in
genome maintenance than do any of the other RAD51 mediators.
brca2-null cells displayed a stronger phenotype than the
brca1, brca2tr,o rrad51 paralog mutant clones
We analyzed cellular tolerance to camptothecin, cisplatin, and
olaparib by measuring cellular survival at 72 hours (7–9 cell cycles)
after continuous exposure to these agents in a liquid medium. We
did not use the conventional colony-formation assay for this
analysis, because the plating efficiency of the brca2-null cells was
only 20%, 5-fold lower than that of wild-type cells. Figure 3A
presents an example of cellular sensitivity to camptothecin, a
DNA-damaging agent. Subsequent figures illustrate the sensitivity
of each mutant, assessed by LC50 values, i.e., the dose that reduces
cell survival to 50% relative to the LC50 value of wild-type cells,
which is defined as 100% (Figure 3B–3E).
In the cellular-survival analysis, the brca2-null cells showed an
increased sensitivity to camptothecin (Figure 3B), cisplatin
(Figure 3C), and olaparib (Figure 3D and 3E). Moreover,
sensitivity to cisplatin and olaparib was higher with the brca2-
null cells than for any of the other HR mutant cells, including the
brca1, rad52, rad54, and xrcc3 clones (Figure 3). We therefore
conclude that BRCA2 plays a more important role in HR-
dependent repair than do the other RAD51 mediators, including
BRCA1, RAD52, RAD54, the RAD51 paralogs, SFR1, and
SWS1.
The less prominent phenotype of the brca2tr cells compared to
the brca2-null cells indicates that the BRCA2 BRC3-truncated
protein retains significant residual HR function. Although brca1
cells were less sensitive to cisplatin and olaparib than were brca2-
null cells, the brca1-null cells exhibited a slightly higher sensitivity to
camptothecin than did the brca2-null cells (Figure 3A). The greater
contribution of BRCA1 to cellular tolerance to camptothecin
might be attributable to the role played by BRCA1 in DNA-
damage responses other than HR, such as collaborative action
with CtIP to eliminate covalently bound oligo-peptides from DSBs
[15].
We next measured the frequency of HR-dependent repair of I-
Sce1-mediated DSBs in a recombination substrate, SCneo, inserted
into the OVALBUMIN locus [44,45] (Table 3). The frequency of
HR-dependent DSB repair was calculated as the number of
neomycin-resistant (neo
+) colonies relative to the number of plated
cells. The frequency of HR in the brca2-null, brca2tr, and brca1 cells
was decreased by 1.5610
4-, 1.5610
2-, and 4.5610
3-fold, respec-
tively, compared with wild-type cells. We conclude that the brca2-
null cells retain residual HR activity, which may account for their
viability even in the complete absence of BRCA2.
Since BRCA2 promotes the loading of RAD51 at damage sites,
we measured RAD51 focus formation at 3 hours after ionizing
radiation. The number of RAD51 foci was reduced but not
eliminated in the brca1 and brca2tr clones, compared with wild-type
cells (Figure 4). These findings are consistent with previous
observations [33,46]. By contrast, we hardly detected any RAD51
focus formation in the brca2-null cells. In conclusion, the BRCA2
protein plays a key role in the efficient recruitment of RAD51 to
DNA-damage sites, but is not essential for every HR reaction.
BRCA2 is required for the effective participation of
BRCA1, RAD52, SFR1, SWS1, and XRCC3 in HR
The idea that RAD51 carries out HR even without BRCA2 led
us to investigate whether or not other RAD51 mediators substitute
for BRCA2 in the promotion of RAD51-dependent HR. To this
end, we deleted the BRCA1, RAD52, SFR1, SWS1, and XRCC3
genes in the conditional brca2-null background, then inactivated
the BRCA2 gene by treating the cells with tamoxifen (Figure 1E).
We also disrupted the RAD54 gene in the conditional brca2-null
background (Table 1). The RAD54 protein promotes HR after the
assembly of RAD51 at DNA-damage sites [47]. To our surprise,
we were able to reproducibly establish all resulting double
mutants, although a substantial fraction (,30%) of the brca2-null
cells died each cell cycle.
The growth kinetics for the brca1/brca2-null, rad52/brca2-null,
sfr1/brca2, sws1/brca2-null, and xrcc3/brca2-null double-mutant
clones was similar to those of the brca2-null single mutant
(Figure 2). Taking the very severe phenotype of brca1 cells into
account, the viability of the brca1/brca2-null cells was surprising.
The cloning efficiency of the brca1/brca2-null cells was slightly
higher than that of the brca2-null single-mutant cells (30%
compared to 20%). Accordingly, the number of spontaneous
chromosomal aberrations in the brca1/brca2-null cells was consis-
tently slightly lower than that in the brca2-null cells (Table 2). In
summary, although the loss of either BRCA1 or BRCA2 greatly
increased the number of spontaneous chromosomal breaks,
inactivation of BRCA1 in the brca2-null cells resulted in a slight
reduction in the severity of the brca2 phenotype.
An early study shows rad52/xrcc3 double-mutant cells are
synthetic lethal and exhibit numerous chromosomal breaks [24],
whereas we here found that the brca2/rad52 and brca2/xrcc3
double-mutant cells were viable. Thus, the synthetic lethality
might be attributable to BRCA2 mediated formation of toxic HR
intermediates, because the brca2/xrcc3 cells exhibit spontaneously
arising isochromatid breaks, where two sisters are broken at the
same site due to defective completion of HR [48]. To test this
hypothesis, we conditionally inactivated the BRCA2 gene in the
rad52/xrcc3 cells (Text S1). We found that the inactivation of the
BRCA2 gene indeed rescued the rad52/xrcc3 cells (Figure S2). This
observation indicates that the synthetic lethality of the rad52/xrcc3
Figure 3. Cellular tolerance to camptothecin, cisplatin, and olaparib. (A) Cells of the indicated genotype were exposed to camptothecin for
72 hours, a period during which wild-type cells are able to divide nine times in the absence of exogenous DNA damage. The X-axis represents the
concentration of camptothecin and the Y-axis represents the relative number of surviving cells at 72 hours. The vertical dotted lines show LC50 values
(the concentration of camptothecin that reduces cellular survival to 50% relative to cellular survival without camptothecin treatment). Relative LC50
values of camptothecin (B), cisplatin (C), and Poly(ADP-ribose) polymerase inhibitor olaparib (D and E) are shown. Values shown are mean 6 SD.
doi:10.1371/journal.pgen.1002148.g003
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RAD52 and XRCC3 depends on BRCA2. Likewise, the
formation of toxic HR intermediates might explain the apparent
discrepancy between the viability of rad52/brca2-null DT40 cells
and the mortality caused by shRNA mediated depletion of RAD52
in brca2 deficient mammalian cells [49], as the latter cells express a
residual amount of RAD52 and truncated BRCA2 proteins
perhaps leading to the formation of toxic HR intermediates.
We next measured the sensitivity of the brca1/brca2-null, rad52/
brca2-null, rad54/brca2-null, sfr1/brca2-null, sws1/brca2-null, and
xrcc3/brca2-null double-mutant clones to camptothecin, cisplatin,
and olaparib (Figure 3 and Figure 5). Remarkably, inactivation of
Figure 4. c-ray–induced Rad51 subnuclear foci in RAD51-mediator mutant cells. (A) Immuno-staining of irradiated wild-type and mutant
DT40 clones using anti-RAD51 antibody. Cells were fixed 3 hours after irradiation with 4Gy c-rays. Bar, 10 mm. (B) Quantification of RAD51 foci in
individual cells of the indicated genotype. Data shown are the means of three experiments. Error bars indicate standard deviation. Statistical analysis
was performed using the t test. * P,0.01 compared to wild-type.
doi:10.1371/journal.pgen.1002148.g004
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agents by more than two-fold. This observation indicates that the
contribution made by BRCA1, the RAD51 paralogs, RAD52,
RAD54, SFR1, and SWS1 to HR depends mostly on BRCA2.
Interestingly, the loss of BRCA1, SFR1, and SWS1 somewhat
increased the cellular tolerance of the brca2-null cells to cisplatin.
Similarly, the loss of SWS1 increased the cellular tolerance of the
brca2-null cells to camptothecin and olaparib. This increased
tolerance was not accompanied by the upregulation of RAD51
focus formation (data not shown). We therefore suggest that, in the
absence of BRCA2, SWS1 has a moderately antagonistic effect on
HR-dependent repair. By contrast, the loss of RAD52 and
XRCC3 significantly increased the cellular sensitivity of the brca2-
null cells to olaparib. In summary, BRCA2 is required for all the
analyzed RAD51 mediators to function, and the functional
relationships between BRCA2 and the other RAD51 mediators
in HR-mediated repair differ slightly depending on the type of
DNA damage.
Discussion
In this study, we established brca2-null cells as well as cells
deficient in each of the RAD51 mediators. We show that BRCA2
plays a more important role in the promotion of both RAD51
polymerization at DNA-damage sites and HR-dependent repair
than does any other RAD51 mediator, including BRCA1, the
RAD51 paralogs, RAD52, SFR1, and SWS1. The ability of brac2-
null cells to proliferate is in marked contrast with the immediate
cell death that occurs upon depletion of RAD51 [1]. Therefore,
RAD51 is able to perform HR even in the absence of BRCA2. To
explore the question of which RAD51 mediators might substitute
for BRCA2 in the promotion of RAD51-dependent HR repair, we
inactivated the RAD51 mediators in brca2-null cells. Loss of any
one of the other RAD51 mediators did not further reduce the
viability of brca2-null cells. In a related study, we also found that the
brca2-null mutant and the palb2/brca2-null double mutant showed
the same phenotype with respect to both spontaneous chromo-
somal aberrations and increased sensitivity to DNA-damaging
agents (manuscript in preparation). Thus we conclude that
BRCA1, PALB2, the RAD51 paralogs, RAD52, SFR1, and
SWS1 all require BRCA2 to contribute to HR.
BRCA2 plays a major role in the recruitment of RAD51 to
DNA–damage sites, but is not essential for every HR
reaction
Data on Ustilago maydis [50] and Arabidopsis thaliana [51] suggest
that BRCA2 might be essential for RAD51 to function in any HR
reaction. However, we here report that RAD51 can form HR
products even in brca2-null cells, indicating that RAD51 plays a
more important role than BRCA2 in HR. This hierarchy between
RAD51 and BRCA2 is supported by previous reports of
experiments with mice, as rad51 null embryos died earlier
(,E6.5) than did BRCA2 null (,E8.5) embryos [52,53]. The
viability of brca2-null DT40 cells is consistent with the clonal
expansion of BRCA2-deficient cells derived from mammary
epithelial lineage-specific or T cell lineage-specific BRCA2-null-
deficient mice [54,55]. Adding to these findings, we here show
solid evidence that vertebrate RAD51 is capable of functioning in
the absence of BRCA2.
Table 1. DT40 mutants used in this study.
Cell line Selection marker for gene disruption Reference or source
sws1 puro/his This study
sfr1 bsr/puro This study
brca2-null hyg/his This study
rad52 bsr/his [69]
rad54 neo/his [70]
xrcc3 bsr/his [71]
brca1 puro/his [46]
brca2tr hyg/his [33]
sws1/brca2-null puro/his This study
sfr1/brca2-null bsr/puro/his This study
rad52/brca2-null hyg/puro/his This study
xrcc3/brca2-null hyg/bsr/puro/his This study
rad54/brca2-null
brca1/brca2-null
neo/bsr/puro/his
hyg/bsr/puro/his
This study
This study
doi:10.1371/journal.pgen.1002148.t001
Table 2. Spontaneous chromosomal aberrations.
Chromatid-type
Chromosome-
type
Cell line Gaps Breaks Gaps Breaks Exchange Total
wild-type 11100 3
xrcc3 11460 1 2
rad54 1.7 0 1.7 0 0.7 4.1
brca1 61 0 062 2 4
brca2-null 16 10 2 18 0 46
brca2tr
brca1/brca2-null
4
0
4
24
3
2
3
13
2
0
16
39
Spontaneous chromosomal aberration of indicated genotypes. Data are the
numbers of aberrations per 100 cells. At least 100 mitotic cells were analyzed
for each genotype.
doi:10.1371/journal.pgen.1002148.t002
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efficient HR
The phenotypic analysis of brca1, brca2-null,a n dbrca1/brca2-null
clones, combining with the previous study of rad51-null cells, reveals
the functional relationship described as follows. The capability of HR
was dramatically diminished when either BRCA1 or BRCA2 was
absent, indicating that the collaboration of BRCA2 and BRCA1 is
required for efficient HR events. brca2-null cells exhibited more
prominent defects in HR than did brca1-null cells, indicating that
BRCA2 can function in HR independently of BRCA1. Moreover,
BRCA29s contribution to the repair of cisplatin-induced interstrand
crosslinks is more significant than BRCA1, which is likely attributable
t ot h ef a c tt h a tB R C A 2 ,b u tn o tB R C A 1 ,f u n c t i o n si nt h eF a n c o n i
anemia repair pathway [56]. BRCA1 has additional functions other
than in HR, such as mediating the damage checkpoint and
processing DSBs [15,57]. The fact that rad51-null cells have a
considerably stronger phenotype than brca2-null cells indicates that
RAD51 could still perform HR-dependent repair in brca2-null cells.
The phenotypic similarities between the brca2-null and the brca1/
brca2-null clones indicate that BRCA1 contributes to HR by
collaborating with BRCA2. Presumably, the two BRCA proteins
form a functional unit and collaborate intimately to load RAD51 at
damage sites. This idea is supported by the fact that BRCA1
physically associates with BRCA2 through the PALB2 protein [58].
However, this idea is challenged by recent studies that suggest that
BRCA1 plays a role in the resection of DSBs [14,59]. One possible
scenario is that the complex formation of BRCA1 and BRCA2 may
allow for close collaboration between the BRCA1-dependent
resection of DSBs and the subsequent loading of RAD51 on the
resulting 39 overhang. Such an interaction interface might be shared
by the E. coli RecBCD complex, which serves as the DSB resection
complex and also interacts directly with RecA following chi site
recognition [60]. In summary, the phenotypic analysis of brca1, brca2-
null,a n dbeca1/brca2-null DT40 clones demonstrates that BRCA1
controls RAD51 in HR, mainly through collaboration with BRCA2.
BRCA2 is required for BRCA1, PALB-2, the RAD51
paralogs, SFR1, and SWS1 to promote HR
Our study reveals that rad52/brca2-null, sfr1/brca2-null, sws1/brca2-
null,a n dxrcc3/brca2-null clones exhibit a phenotype very similar to
that of brca2-null cells (Figure 5). In a separate study, we conformed
phenotypic similarity between brca2-null and palb2/brca2-null clones
(datanotshown).Wethereforesuggestthat,likeBRCA1,PALB2,the
RAD51 paralogs, RAD52, SFR1, and SWS1 are also able to
participate in HR, mostly depending on BRCA2. One possible
scenario is that BRCA2 is recruited to DNA-damage sites through
PALB2 or by directly interacting with the junction between the
duplex DNA and the single-strand sequences [61]. BRCA2 might
thus serve as a platform to recruit various RAD51 mediators to the
appropriate positions of DNA-damage sites (Figure 6).
Applications for clinical research
DT40 is a unique cell line that offers a panel of DNA-repair-
deficient isogenic mutants derived from a stable parental line.
DT40 cells have several characteristics that affect cellular
responses to anti-cancer agents. First, DT40 appears, for unknown
reasons, to possess a significantly higher HR efficiency than any
mammalian cell line [43]. The efficient HR in DT40 cells is
prominent particularly in HR between diverged homologous
sequences such as Immunoglobulin V gene diversification [62] and
gene targeting, where the selection marker genes of gene-
disruption constructs may interfere with HR as heterologous
sequences. Second, like many cancer cells, DT40 lacks the
functional p53, and as a result has no G1/S damage checkpoint
[63]. In addition, 70% of the DT40 cell cycle takes place in the S
phase. Thus, DNA damage at any phase of the cell cycle may have
a direct impact on DNA replication. These characteristics, specific
to DT40, suggest that a defect in DNA repair associated with
DNA replication, including HR-mediated DNA repair, may
display a more prominent phenotype in DT40 cells than in other
cell lines that have a longer G1 phase and/or a normal G1/S
checkpoint. Bearing this in mind, DT40 is revealed as a unique
and valuable tool and has been used extensively to explore the role
of individual HR factors responsible for cancer therapy.
Materials and Methods
Cell culture and DNA transfection
Cells were aquired and cultured as described previously [1,43].
All mutants were isolated from single colonies. DNA transfection
Table 3. Double strand break-induced gene conversion frequency.
Cell line Relative recombination frequency ± SE Range of neo
+ colonies per 1610
7 transfected cells (range)
wild-type 1.060.8 1.1,2.5610
5
xrcc3 1.360.1610
21 1.3,2.0610
4
brca1 2.260.4610
24 20,36
brca2-null 6.860.9610
25 4,11
brca2tr 6.664.2610
23 347,1493
sws1/brca2-null 7.161.5610
25 8,15
sfr1/brca2-null 5.660.2610
25 6,13
rad52/brca2-null 4.460.2610
25 5,10
xrcc3/brca2-null 3.061.1610
25 2,13
rad54/brca2-null 7.661.6610
25 7,20
brca1/brca2-null 1.960.5610
25 1,7
Analysis of HR frequency induced by I-Sce1-induced DSBs in an artificial substrate. SCneo-puro was stably integrated into the OVALBUMIN locus of indicated genotypes
by gene-targeting. 1.0610
7 cells of each genotype were transfected with 30 mg of either I-Sce1 expression vector or pBluescript KS, and subsequently selected using a
neomycin analog (G418). The ratio of recombination frequency was calculated by comparing the number of G418 resistant clones in the mutant cell lines to that in the
wild-type cell line. Only results obtained using the I-Sce1 expression vector are shown.
doi:10.1371/journal.pgen.1002148.t003
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Details of the cell lines used in this study are shown in Table 1.
Generation of SFR1
2/2 DT40 cells
To disrupt the SFR1 gene, we generated SFR1-puro and SFR1-bsr
disruption constructs by combining two genomic PCR products
with the puro- or bsr-selection-marker cassette. Genomic DNA
sequences were amplified using the 59-CCCGGTACTGAG-
GGGTGCGATTGCTTGCAGG-39 and 59-CCCTTAGAGTT-
GCACTCATTGGCTAAAG-39 primers for the upstream arm,
and the 59-GGCTCAAACTGGTCAAGATGTACCGATCTA-
AGG-39 and 59-CCACCAGCATCCACTAAAGGGCAAGGA-
Figure 5. Effect of brca2 deletion on sws1-, sfr1-, rad52-, rad54-, xrcc3-, and brca1-deficient cells. Cellular sensitivities to the indicated DNA
damaging agents were analyzed using the same method as in Figure 3. The LC50 values are shown in Figure 3B–3E.
doi:10.1371/journal.pgen.1002148.g005
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were cloned into pCR2.1-TOPO vector (Invitrogen). The 1.7 kb
fragment of the upstream arm was cloned into the KpnI site of
pCR2.1 containing the 3.0 kb downstream arm. Marker-gene
cassettes were inserted at the BamHI site of the resulting plasmid.
To generate SFR1
2/2 cells, SFR1-puro and SFR1-bsr disruption
constructs lineralized with NotI were transfected sequentially by
electroporation (Bio-Rad). The genomic DNA of the transfectants
was digested with both BamHI and EcoRI, and gene-targeting
events were confirmed by Southern blot analysis. The probe was
prepared from a PCR-amplification of DT40 genomic DNA using
primers 59-GAACAGCACCACGCAATTCA-39 and 59-CCT-
TAGAGTTGCACTCATTGG-39.
Cloning of SFR1 cDNA
Chicken SFR1 cDNA was isolated by PCR amplification of the
primary cDNAs using the 59-GTTGAGATGGAGGAAGC-
AGCGTGTGGTAAA-39 and 59-CACCACTCAATTCCACTT-
CAAAGAG-39 primers. The gene bank accession number of the
chicken SFR1 gene is XM-001234167.
Generation of SWS1
2/2 DT40 cells
To disrupt the SWS1 gene, we generated SWS1 gene-disruption
constructs containing the 2.6 kb upstream and the 3.0 kb
downstream genomic fragments. The 2.6 kb fragment was PCR-
amplified using the 59-ggggacaactttgtatagaaaagttgTTCTTACGT-
CACTCCAGAAGAACA-39 and 59-ggggactgcttttttgtacaaacttgC-
CAAGTCTGTGAATCGCAGAAGCA-39 primers. The 3.0 kb
fragment was PCR-amplified using the 59-ggggacagctttcttgta-
caaagtggAATTCCAAGCAGTTCCACATCTCT-39 and 59-gg-
ggacaactttgtataataaagttgGTATGGCTCCTGTCAGGTTAGAG-
T-39 primers. Note that the underlined sequences denote the
recognition sequences in the Gateway system (Invitrogen). Using
the MultiSite Gateway system with pENTR-lox-his, pENTR-lox-
puro and pDEST-DTA-MLS [65], a floxed his or puro gene was
inserted between the upstream and downstream arms on a plasmid
carrying a diphtheria toxin A (DT-A) gene, thus yielding the two
targeting vectors, SWS1-his/loxP and SWS1-puro/loxP.
To generate SWS1
2/2 cells, SWS1-his/loxP and SWS1-puro/loxP
gene-disruption constructs linearized with AscI were transfected
sequentially into DT40 cells (Bio-Rad). The genomic DNA of the
DNA double-strand break
BRCA2         RAD51 paralogs        BRCA1        PALB2          SWS1      SFR1
RAD51 performs homologous recombination without BRCA2
BRCA2 orchestrates the loading of RAD51 at damaged sites
RAD51
Figure 6. Model of BRCA2 dependent regulation of various RAD51 mediators at DNA–damage sites. In the absence of BRCA2, RAD51
polymer assembles at DNA damage sites (top), while BRCA2 significantly promotes the polymerization of RAD51 (bottom). This promotion is
attributable to the requirement of BRCA2 for the appropriate localization of other RAD51 mediators at DNA damage sites. Accordingly, the loss of
BRCA2 may result in the abnormal functioning of some RAD51 mediators, for example, SWS1. This scenario explains why the loss of SWS1 increased
cellular tolerance to camptothecin, cisplatin, and olaparib only when BRCA2 was absent (Figure 3).
doi:10.1371/journal.pgen.1002148.g006
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targeting events were confirmed by Southern-blot analysis. The
probe was prepared by PCR-amplification of chicken genomic
DNA using the 59-GCTCGCAGGAACACAACTCCTT-39 and
59-GTACAGGAGTGTTTCTCTGCGG-39 primers.
Cloning of SWS1 cDNA
The gene bank accession numbers for the human and chicken
Sws1 genes are XP-058899 and XP-415841, respectively. RT-
PCR of DT40 transcripts was done using the 59-CGCGTCGA-
CATGGATAGCACCTTACCAGCT-39 and 59-CGCGGAT-
CCTCATCCTTCATCCTCTTCCTC-39 primers.
Generation of BRCA2
2/2 DT40 cells
The brca2-null mutant cells were generated as follows (Figure 1).
We inserted conditional brca2 heterozygous cells (BRCA2
+/con1)
harboring two loxP signals into the other allele upstream of the
promoter and downstream of exon 2. Construction of the BRCA2
conditional-null targeting vector was carried out as described
previously [33]. To delete the intact allele of the BRCA2
+/con1 cells,
we constructed a targeting vector to delete all exons of the BRCA2
gene. The ,6. kb and ,3.5 kb fragments at the BRCA2 locus [66]
were amplified from DT40 genomic DNA by using the 59-
CCGCTCGAGTTTTGTTAGTTGTGAGATGTG-39 and 59-
TTATCGGGGCTTTGTCAGCTTTAGCTTCTC-39 primers
and the 59-CGGAGTTGAATAATGGTACATTTCTGGCAC-
39 and 59-GTTGAATTTGAAACTGGCTGAACAGAAGAG-39
primers, respectively. Both fragments were cloned into TOPO-
pCRXL cloning vector (Invitrogen, Carlsbad, California) to
make the topo/6.0 kb and topo/3.5 kb vectors. The ,5.2 kb
NotI fragment from the topo/6.0 kb vector was inserted into the
NotI site in the multicloning site of the topo/3.5 kb vector,
resulting in the pUpper/Lower vector. Finally, a loxP-flanked
puro-resistance cassette was inserted into the BglII site in the
pUpper/Lower vector. The resulting targeting construct was
transfected into the BRCA2
+/con1 cells followed by selection with
puromycin. The genomic DNA of the transfectants was digested
with XbaI, and gene-targeting events were confirmed by
Southern-blot analysis with a probe that was amplified from
genomic DNA using the 59-ATCCATGTCACTGTTGA-
CATCCTGACTGCC-39 and 59-AGATACAAACCCAATGG-
GAAGCCAGGTGTG-39 primers. The bands detected by the
p r o b ew e r e8 . 6k bf r o mt h ewild-type allele and 5.2 kb from the
targeted allele.
Upon exposure of the BRCA2
2/con1 cells to tamoxifen, an
estrogen antagonist, nucleotide sequences, including promoter and
coding sequences encoding the initiation codon to the 67th amino
acid, were excised by a chimeric Cre recombinase fused to the
estrogen-receptor ligand-binding domain [24], leading to the
complete disruption of the BRCA2 gene.
Disruption of individual HR genes in BRCA2
2/2 DT40 cells
To disrupt RAD51 mediator genes in BRCA2
2/2 DT40 cells, we
disrupted each gene in the BRCA2
2/con1 cells (Table 1). We
exposed the resulting RAD51 mediator
2/2/BRCA2
2/con1 cells to
tamoxifen and isolated the RAD51 mediator
2/2/BRCA2
2/2 cells.
Western blot analysis
Western blotting was performed as previously described [33].
The rabbit polyclonal primary antibody, which recognizes the N-
terminal 203 amino acids of chicken BRCA2, was diluted 1:100
with blocking buffer. The anti-rabbit IgG HRP conjugated
antibody was diluted 1:5000 with blocking buffer.
Flow-cytometric analysis
To measure growth kinetics, cells were counted daily using flow-
cytometric analysis, as described previously [7]. To measure cell-
cycle distribution, cells (5610
5/ml) were labeled for 10 minutes
with 20 mmol/L 5-bromo-29-deoxyuridine (BrdU) and subse-
quently harvested. Harvested cells were fixed and analyzed as
previously described [7].
Measurement of cellular sensitivity to camptothecin,
cisplatin, and olaparib in liquid culture
To measure cellular survival, cells (1.5610
3–1.5610
4)w e r e
incubated in 1 ml culture medium per well containing various
concentrations of the DNA-damaging agents. At 72 hours, the ATP
in the cellular lysates was measured to assess the number of live cells.
The camptothecin (TopoGen Inc., Colombus, OH) and olaparib
(AstraZeneca) were diluted with DMSO, and the cisplatin (Nihon-
kayaku, Tokyo, Japan) was diluted with PBS. To measure the
sensitivity of the DT40 cell lines to these agents, cells were continuously
exposed to various concentrations of the drug and the number of cells
was measured at 72 hours. At least three independent experiments
were carried out. Sensitivity was calculated by dividing the number of
cells treated with the drug by the number of untreated cells [8].
Measurement of ATP to assess cellular sensitivity to DNA
damaging agents
To assess cell numbers after treatment with the genotoxic
reagents, we measured the amount of ATP in the whole cell lysate
[67].
Visualization of RAD51 foci
Cells were harvested at 3 hours after gamma irradiation. Cells
were spun onto slides using a Shandon Cytospin 3 centrifuge
(Shandon, Pittsburgh, Pa.). Staining and visualization of RAD51
foci were carried out as previously described [34] using rabbit
polyclonal antibody, which recognizes human RAD51, at a
dilution of 1:500 (Calbiochem, San Diego, CA San Diego, CA),
and Alexa Fluor 488 goat anti-human IgG antibody at a dilution
of 1:1000 (Molecular Probes Inc., Eugene, OR [34]).
Analysis of chromosomal aberrations
Measurement of chromosomal aberrations was performed as
described previously [68].
Measurement of HR frequencies for I-Sce1–induced DSB
repair
Measurement of recombination frequencies for I-SceI-induced
DSB repair was performed as described previously [34,44].
Modified SCneo was inserted into the previously described
OVALBUMIN gene construct and targeted into the OVALBUMIN
locus in wild-type, xrcc3, brca1, brca2, and brca2tr DT40 clones. For
transient transfections, 1610
7 cells were suspended in 0.5 ml of
phosphate-buffered saline, mixed with 30 mgo fI - SceI expression
vector (pCBASce) or pBluescript KS without linearization, and
electroporated at 250 V, 960 microfarads. At 24 hours after
electroporation, the cells were plated in 96-well plates with or
without 2.0 mg/ml neomycin analog (G418). The cells were
grown for 7 to 10 days, after which formed colonies were counted.
HR frequency was calculated by dividing the number of
neomycin-resistant colonies by the number of plated cells.
Statistical analysis
Survival data were log-transformed giving approximate nor-
mality. Analysis of covariance (ANCOVA) was used to test for
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a series of mutant cells or brca2-null cells and a series of double-
knockout mutant cells. Viability of the DT40 cells was estimated
using regressing curves. Regression-curve equations were used to
calculate LC50 (50% lethal concentration) values. Relative LC50
values were normalized according to the LC50 value of the
parental wild-type cells.
Supporting Information
Figure S1 Generation of BRCA2
2/2 (ver.2) cells. (A) Experi-
mental methods to generate BRCA2
2/2 (ver.2) cells. (B) Schematic
representation of the BRCA2 conditional-null allele-2. The conditional-
null allele-2 (con2) was generated by targeting the his selection-
marker gene flanked by two loxP signals (ploxP-his) in intron 12 of
the BRCA2 conditional allele 1. Treatment of the BRCA2
2/con2
cells causes deletion from the promoter to exon 11, encoding all
BRC motifs. The relevant XhoI sites in the conditional-null allele-1
and the position of the probe used in the Southern-blot analysis
are indicated. The solid boxes and arrowheads represent the exons
and loxP signals, respectively.
(EPS)
Figure S2 Proliferation and spontaneous chromosomal aberra-
tions of brca2/rad52/xrcc3 triple knockout cells. (A) Growth
kinetics of the indicated cell cultures in the absence (right) and
presence (left) of TAM. Each value represents the averaged results
from two separate clones. (B) Cell viability was assessed by flow
cytometric analysis of PI uptake and forward scatter (FSC)
representing the cell size after tamoxifen (TAM) treatment 4 days.
A fixed number of plastic beads was added before flow cytometric
analysis to calibrate cell number. Cells falling in the R1 and R2
gates identify dead and viable cells, respectively, and numbers
given show their percentages. (C) Spontaneous chromosomal
aberrations in cells with indicated genotype after tamoxifen (TAM)
treatment 6 days. The data shown in the histogram indicate the
types and numbers of chromosomal breaks in 50 analyzed mitotic
cells. Two breaks at the same site of both sister chromatids are
defined as isochromatid breaks, while breaks at either sister
chromatid are chromatid breaks.
(EPS)
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